Souhaitez-vous accéder aux communiqués récents ?

Pluristyx issued Japan patent allowance for next-gen synthetic mRNA, accelerating non-viral, footprint-free iPSC generation for regenerative medicine

More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97%No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient...

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient...

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case...

Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in...

SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...

Longeveron will present at BIO 2026. CEO, CFO & BD will host meetings to explore partnership opportunities for its 4 stem cell therapy developmet programs.

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)...

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...

David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of DirectorsZachary Roberts, M.D.,...